$0.00
(Market cap
$12 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
55,971,338
10 Years Aggregate
CFO
$-240.56 Mln
EBITDA
$-298.29 Mln
Net Profit
$-293.39 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PDS Biotechnology Corp (PDSB)
| -72.2 | -69.4 | -80.2 | -82.7 | -67.0 | -57.2 | -48.9 |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
PDS Biotechnology Corp (PDSB)
| -52.8 | -66.9 | -62.3 | 63.0 | 278.5 | -19.2 | -58.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PDS Biotechnology Corp (PDSB)
|
0.2 | 11.8 | 0.0 | -33.7 | -- | -- | -- | 3.5 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical... trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey. Read more
-
President, CEO & Director
Dr. Frank K. Bedu-Addo Ph.D.
-
President, CEO & Director
Dr. Frank K. Bedu-Addo Ph.D.
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for PDS Biotechnology Corp (PDSB)
What is the current share price of PDS Biotechnology Corp (PDSB) Today?
The share price of PDS Biotechnology Corp (PDSB) is $0.21 (NASDAQ) as of 31-Aug-2026 16:20 EDT. PDS Biotechnology Corp (PDSB) has given a return of -67.03% in the last 3 years.
What is the current PB & PE ratio of PDS Biotechnology Corp (PDSB)?
Since, TTM earnings of PDS Biotechnology Corp (PDSB) is negative, P/E ratio is not available.
The P/B ratio of PDS Biotechnology Corp (PDSB) is 3.47 times as on 28-Aug-2026, a 33 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.04 |
3.86 |
2024 |
-1.58 |
3.13 |
2023 |
-3.67 |
6.02 |
2022 |
-9.29 |
8.63 |
2021 |
-13.61 |
3.64 |
What is the 52 Week High and Low of PDS Biotechnology Corp (PDSB)?
The 52-week high and low of PDS Biotechnology Corp (PDSB) are Rs 1.55 and Rs 0.20 as of 01-Sep-2026.
What is the market cap of PDS Biotechnology Corp (PDSB)?
PDS Biotechnology Corp (PDSB) has a market capitalisation of $ 12 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in PDS Biotechnology Corp (PDSB)?
Before investing in PDS Biotechnology Corp (PDSB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.